Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Price Target at $66.67

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $66.6667.

Several equities analysts recently weighed in on RVPH shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RVPH. Armistice Capital LLC acquired a new position in Reviva Pharmaceuticals in the 2nd quarter worth about $1,026,000. Geode Capital Management LLC grew its holdings in Reviva Pharmaceuticals by 87.6% in the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after purchasing an additional 489,711 shares during the period. State Street Corp increased its position in shares of Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after buying an additional 256,500 shares in the last quarter. Millennium Management LLC increased its position in shares of Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after buying an additional 223,178 shares in the last quarter. Finally, Lido Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $0.50 on Friday. The firm has a market cap of $6.61 million, a price-to-earnings ratio of -0.12 and a beta of 0.53. The firm has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $1.76. Reviva Pharmaceuticals has a one year low of $0.26 and a one year high of $17.20.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). As a group, equities analysts predict that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.